Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.
meta-analysis
pneumococcal conjugate vaccine
serotype 3
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
30 05 2019
30 05 2019
Historique:
received:
01
08
2018
accepted:
22
10
2018
pubmed:
26
10
2018
medline:
29
7
2020
entrez:
26
10
2018
Statut:
ppublish
Résumé
The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have shown inconsistent results. We performed a systematic review and meta-analysis of observational studies to assess PCV13 vaccine effectiveness (VE) for serotype 3 IPD in children. We systematically searched PubMed, Embase, and the Cochrane library for studies published before 14 August 2017. We identified 4 published studies and 2 conference posters that provided PCV13 VE estimates stratified by serotype. The pooled PCV13 VE against serotype 3 IPD from the random-effects meta-analysis was 63.5% (95% confidence interval [CI], 37.3%-89.7%). A sensitivity analysis including conference posters gave a pooled VE estimate of 72.4% (95% CI, 56.7%-88.0%). The pooled data from case-control studies with similar methodologies and high quality support direct PCV13 protection against serotype 3 IPD in children.
Identifiants
pubmed: 30357326
pii: 5142858
doi: 10.1093/cid/ciy920
pmc: PMC6541704
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2135-2143Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Biometrics. 1975 Sep;31(3):643-9
pubmed: 1100136
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Vaccine. 2011 Nov 15;29(49):9127-31
pubmed: 21983361
Pediatr Infect Dis J. 2012 Mar;31(3):297-301
pubmed: 22330166
Vaccine. 2012 Jun 8;30(27):4067-72
pubmed: 22525797
Int J Technol Assess Health Care. 2012 Apr;28(2):138-44
pubmed: 22559755
JAMA. 2013 Sep 4;310(9):930-7
pubmed: 24002279
Vaccine. 2013 Dec 16;31(52):6232-8
pubmed: 24176490
Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):879-910
pubmed: 24563274
Clin Infect Dis. 2014 Oct 15;59(8):1066-73
pubmed: 25034421
Lancet Infect Dis. 2014 Sep;14(9):839-46
pubmed: 25042756
World J Methodol. 2012 Aug 26;2(4):27-32
pubmed: 25237614
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Vaccine. 2016 Apr 19;34(18):2062-5
pubmed: 26920471
Lancet Respir Med. 2016 May;4(5):399-406
pubmed: 26987984
Int J Epidemiol. 2016 Dec 1;45(6):2060-2074
pubmed: 27453361
PLoS One. 2016 Aug 15;11(8):e0161257
pubmed: 27526117
Heliyon. 2016 Nov 29;2(11):e00198
pubmed: 27957553
Vaccine. 2017 Feb 7;35(6):945-950
pubmed: 28087146
Lancet Respir Med. 2017 Aug;5(8):648-656
pubmed: 28359798
Vaccine. 2017 Sep 25;35(40):5406-5417
pubmed: 28602602
PLoS One. 2017 Aug 14;12(8):e0183191
pubmed: 28806737
Expert Rev Vaccines. 2018 Jan;17(1):71-78
pubmed: 29164952
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
Thorax. 2019 May;74(5):473-482
pubmed: 30355641
PLoS Pathog. 2018 Nov 26;14(11):e1007438
pubmed: 30475919
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
N Engl J Med. 1980 Sep 4;303(10):549-52
pubmed: 6995835